License agreement for molecular glue targeting PP2A
Rappta Therapeutics, a company developing anti-cancer drugs, has entered a global license agreement with SpringWorks Therapeutics for RPT04402, a first-in-class molecular glue of specific protein phosphatase 2A (PP2A) complexes. Rappta’s PP2A-reactivating technologies are developed using high resolution structural data and have the potential to create a new class of anti-cancer… Read More